NO943260D0 - Microsomal triglyceride transfer protein - Google Patents

Microsomal triglyceride transfer protein

Info

Publication number
NO943260D0
NO943260D0 NO943260A NO943260A NO943260D0 NO 943260 D0 NO943260 D0 NO 943260D0 NO 943260 A NO943260 A NO 943260A NO 943260 A NO943260 A NO 943260A NO 943260 D0 NO943260 D0 NO 943260D0
Authority
NO
Norway
Prior art keywords
transfer protein
microsomal triglyceride
triglyceride transfer
microsomal
protein
Prior art date
Application number
NO943260A
Other languages
Norwegian (no)
Other versions
NO943260L (en
Inventor
Ii John R Wetterau
Daru Young Sharp
Richard E Gregg
Scott A Biller
John K Dickson
R Michael Lawrence
John E Lawson
Henry M Holava
Richard A Partyka
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO943260D0 publication Critical patent/NO943260D0/en
Publication of NO943260L publication Critical patent/NO943260L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
NO943260A 1993-09-03 1994-09-02 Microsomal triglyceride transfer protein NO943260L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/117,362 US5595872A (en) 1992-03-06 1993-09-03 Nucleic acids encoding microsomal trigyceride transfer protein

Publications (2)

Publication Number Publication Date
NO943260D0 true NO943260D0 (en) 1994-09-02
NO943260L NO943260L (en) 1995-03-06

Family

ID=22372489

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943260A NO943260L (en) 1993-09-03 1994-09-02 Microsomal triglyceride transfer protein

Country Status (16)

Country Link
US (4) US5595872A (en)
EP (1) EP0643057A1 (en)
JP (1) JPH07165712A (en)
KR (1) KR950008505A (en)
CN (1) CN1106003A (en)
AU (1) AU690125B2 (en)
CA (1) CA2131430A1 (en)
CZ (1) CZ212494A3 (en)
FI (1) FI944048A (en)
HU (1) HUT70613A (en)
IL (1) IL110803A0 (en)
NO (1) NO943260L (en)
NZ (1) NZ264372A (en)
PL (1) PL304883A1 (en)
RU (1) RU94031747A (en)
ZA (1) ZA946772B (en)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
US5919795A (en) * 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
PT832069E (en) * 1995-06-07 2003-06-30 Pfizer BIPHENYL-2-CARBOXYLIC ACID TETRAHYDRO-ISOQUINOLIN-6-YLIDATE AND THEIR PREPARATION AND ITS USE AS MICROSOMAL TRIGLYCERID TRANSFERENCE PROTEIN INHIBITORS AND / OR APOLIPOPROTEIN B SECRECY (APO B)
SK283408B6 (en) * 1995-06-07 2003-07-01 Pfizer Inc. Amides and pharmaceutical preparations based on them
ES2218660T3 (en) * 1996-01-16 2004-11-16 Bristol-Myers Squibb Company AROMATIC INHIBITORS CONFORMALLY RESTRICTED FROM THE MICROSOMAL TRIGLICERID TRANSFER PROTEIN AND PROCEDURE.
WO1997041111A1 (en) * 1996-04-30 1997-11-06 Pfizer Inc. Processes and intermediates for preparing 4'-trifluoromethylbiphenyl-2-carboxylic acid [2-(2h-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-amide
US5827875A (en) * 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) * 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JP2002513379A (en) * 1996-07-24 2002-05-08 ブリストル―マイヤーズ・スクイブ・カンパニー Treatment of tumors with high LDL requirements using MTP inhibitors
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US5989873A (en) * 1996-09-24 1999-11-23 Vinayagamoorthy; Thuraiayah Method of detecting gene expression and/or of preventing such expression in cells
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) * 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
EP0989852A4 (en) * 1997-01-17 2002-11-13 Bristol Myers Squibb Co Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
US5929091A (en) * 1997-03-12 1999-07-27 Warner-Lambert Company Method of lowering plasma levels of lipoprotein(a)
WO1998054135A1 (en) 1997-05-30 1998-12-03 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
US6767739B2 (en) * 2001-07-30 2004-07-27 Isis Pharmaceuticals Inc. Antisense modulation of microsomal triglyceride transfer protein expression
US6218524B1 (en) * 1997-09-16 2001-04-17 Eurona Medical Ab Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof
JP2959765B2 (en) 1997-12-12 1999-10-06 日本たばこ産業株式会社 3-piperidyl-4-oxoquinazoline derivative and pharmaceutical composition containing the same
EP1085846A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6780883B2 (en) 1998-11-05 2004-08-24 Warner-Lambert Company Amide inhibitors of microsomal triglyceride transfer protein
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
KR20020005662A (en) 1999-04-09 2002-01-17 기따자또 이찌로 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same
SE9902987D0 (en) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
KR100879647B1 (en) * 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 Azacyclic compounds for use in the treatment of serotonin related diseases
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001262185A1 (en) * 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
DE10030375A1 (en) * 2000-06-21 2002-01-03 Bayer Ag Use of MTP inhibitors to lower ppTRL
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Biphenylcarboxamides useful as lipid lowering agents
FR2816940A1 (en) * 2000-11-23 2002-05-24 Lipha New 4-(biphenyl carbonylamino) piperidine derivatives are microsomal triglyceride transfer protein and apoprotein B secretion inhibitors used for treating e.g. hypercholesterolemia and obesity
AR031930A1 (en) * 2000-12-22 2003-10-08 Schering Corp MCH ANTAGONISTS AND ITS USE IN THE TREATMENT OF OBESITY
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US6774112B2 (en) 2001-04-11 2004-08-10 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
IL158516A0 (en) 2001-06-28 2004-05-12 Pfizer Prod Inc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
CA2463908A1 (en) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
AU2002360561A1 (en) * 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
BR0215429A (en) * 2001-12-28 2004-12-14 Acadia Pharm Inc Compound of formula I and its uses, activity inhibition methods and monoamine receptor activation inhibition method, treatment methods, genetic polymorphism identification method and patient identification method
US6747048B2 (en) 2002-05-08 2004-06-08 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
JP4478563B2 (en) * 2002-05-14 2010-06-09 プレゼント インヴェストメンツ エルエルシー Transmission signal forming method
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
NZ537522A (en) * 2002-06-24 2006-07-28 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
DE60332856D1 (en) * 2002-10-23 2010-07-15 Bristol Myers Squibb Co GLYCINNITRIL BASED DIPEPTIDYLPEPTIDASE IV INHIBITORS
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
EP2009000B1 (en) 2003-01-16 2011-06-08 Acadia Pharmaceuticals Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
JP2006516620A (en) * 2003-01-24 2006-07-06 ブリストル−マイヤーズ　スクイブ　カンパニー Cycloalkyl-containing anilide ligands in thyroid receptors.
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
SE0301369D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2545311C (en) 2003-11-12 2012-01-03 Phenomix Corporation Heterocyclic boronic acid compounds
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AP2006003685A0 (en) 2004-02-04 2006-08-31 Pfizer Prod Inc Substituted quinoline compounds
WO2005087234A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US20080280922A1 (en) * 2004-04-09 2008-11-13 Marc Alois Celine Maria Engelen Intermittent Dosing Regimen For Overweight and Obese Subjects
TWI396686B (en) * 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
JP2008504523A (en) * 2004-06-25 2008-02-14 ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク Fluorescence assay for MTP activity
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) * 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7786163B2 (en) * 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
KR101389246B1 (en) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AR051446A1 (en) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
MX2007003433A (en) * 2004-09-27 2007-08-06 Acadia Pharm Inc Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4- (2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms.
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
SE0403117D0 (en) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
US7635699B2 (en) * 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) * 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR20080026117A (en) * 2005-05-26 2008-03-24 브리스톨-마이어스 스큅 컴퍼니 N-terminally modified glp-1 receptor modulators
JP2008542255A (en) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク Combination of cannabinoid-1 receptor antagonist and microsomal triglyceride transfer protein inhibitor for the treatment of obesity or maintenance of weight loss
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US20070093468A1 (en) * 2005-10-18 2007-04-26 Wisler Gerald L Methods for treating disorders associated with hyperlipidemia in a mammal
EP2487154B1 (en) 2005-10-31 2013-10-16 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
JP2007169627A (en) * 2005-11-28 2007-07-05 Konica Minolta Medical & Graphic Inc Photocurable composition, active ray-curable type ink composition and image forming method
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2009523177A (en) * 2006-01-11 2009-06-18 ブリストル−マイヤーズ スクイブ カンパニー Human glucagon-like peptide-1 modulator and its use in the treatment of diabetes and related conditions
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080044326A1 (en) * 2006-07-04 2008-02-21 Esencia Co., Ltd. Sterilizer for baby products
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP5525261B2 (en) 2006-10-24 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ MTP-inhibiting tetrahydro-naphthalene-1-carboxylic acid derivative
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Piperidine Or Piperazine Substituted Tetrahydro-Naphthalene-1-Carboxylic Acid Mtp Inhibiting Compounds.apoB
EP2094692B1 (en) 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
JP2010508358A (en) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー Glucocorticoid receptor, AP-1 and / or modulator of NF-κB activity, and use thereof
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2120927A1 (en) * 2006-12-21 2009-11-25 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
UY30892A1 (en) * 2007-02-07 2008-09-02 Smithkline Beckman Corp AKT ACTIVITY INHIBITORS
ES2423485T3 (en) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Associations of 5-HT2A inverse agonists and antagonists with antipsychotics
PE20090185A1 (en) 2007-03-22 2009-02-28 Bristol Myers Squibb Co PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
CN101687873A (en) 2007-04-17 2010-03-31 百时美施贵宝公司 11 beta-hydroxysteroid dehydrogenase type i inhibitors with annelated heterocycles
PE20090696A1 (en) 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
EP2147008A2 (en) * 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009018065A2 (en) * 2007-07-27 2009-02-05 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
KR101107425B1 (en) 2007-08-23 2012-01-19 테라코스, 인코포레이티드 Benzylbenzene derivatives and methods of use
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
US20090082388A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals Inc. Co-administration of pimavanserin with other agents
AU2008304231A1 (en) * 2007-09-27 2009-04-02 Albany Molecular Research, Inc. Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
EP2247597A1 (en) 2008-02-07 2010-11-10 Bristol-Myers Squibb Company Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
WO2009133834A1 (en) * 2008-04-28 2009-11-05 塩野義製薬株式会社 Keto-amide derivative having inhibitory activity on endothelial lipase
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2011525537A (en) 2008-06-24 2011-09-22 ブリストル−マイヤーズ スクイブ カンパニー Cyclopentathiophene modulators of glucocorticoid receptor, AP-1, and / or NF-κB activity and uses thereof
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
CA2730734C (en) * 2008-07-15 2017-04-25 Theracos, Inc. Deuterated 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene compounds having sodium glucose cotransporter inhibitory activity
MA32998B1 (en) * 2009-01-30 2012-01-02 Glaxosmithkline Llc N-{{1-s) -2-amino-1-[(3-fluorophenyl) methyl]} ethyl-5-chloro-4 (4-chloro-1-methyl-1h-pyrazol-5 -yl) Crystalline theophenicarboxamide
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2429296B1 (en) * 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
MX2011011901A (en) 2009-05-12 2012-01-20 Albany Molecular Res Inc Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof.
JP5739415B2 (en) * 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S) -7-([1,2,4] triazolo [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydroisoquinoline Crystal forms and uses thereof
BR112012011274A2 (en) 2009-11-13 2016-04-12 Astrazeneca Uk Ltd reduced mass metformin formulation and its combination
ES2693686T3 (en) 2009-11-13 2018-12-13 Astrazeneca Ab Immediate-release tablet formulations
HUE040486T2 (en) 2009-11-13 2019-03-28 Astrazeneca Ab Bilayer tablet formulations
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
AU2011254658B2 (en) 2010-05-19 2016-02-18 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
WO2011144656A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Preparation of posaconazole intermediates
EP2571847B1 (en) 2010-05-19 2016-09-21 Sandoz AG Process for the preparation of chiral hydrazides
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
CA2804926C (en) 2010-07-09 2019-01-08 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
EP2600716A4 (en) 2010-08-03 2014-02-19 Beth Israel Hospital Methods and compositions for treatment of metabolic disorders
TWI631963B (en) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US9493428B2 (en) 2011-06-16 2016-11-15 Sandoz Ag Process for the preparation of a chiral compound
CN108440614A (en) 2012-11-20 2018-08-24 莱西肯医药有限公司 The inhibitor of sodium glucose cotransporter 1
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
DK3325444T3 (en) 2015-07-20 2021-10-04 Acadia Pharm Inc PROCEDURES FOR THE PREPARATION OF N- (4-FLUOROBENZYL) -N- (1-METHYLPIPERIDIN-4-YL) -N '- (4- (2-METHYLPROPYLOXY) PHENYLMETHYL) CARBAMID AND DETSMAL PARTHOLE
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN107935854A (en) * 2017-10-30 2018-04-20 广东莱佛士制药技术有限公司 A kind of synthetic method of γ dialkyl group N-Propyl Bromide
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
AU2019346497A1 (en) 2018-09-26 2021-04-08 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
EP4188372A1 (en) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
WO2022187463A1 (en) 2021-03-03 2022-09-09 Amryt Pharmaceuticals Inc. Methods for treating familial chylomicronemia syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1404868A (en) * 1972-12-21 1975-09-03 Wyeth John & Brother Ltd Pyridine tetrahydropyridine and piperidine derivatives
US4772549A (en) * 1986-05-30 1988-09-20 Biotechnology Research Partners, Ltd. Polymorphisms related to lipid metabolism: ApoB, ApoCII, ApoE, ApoAIV
DE3600390A1 (en) * 1986-01-09 1987-07-16 Hoechst Ag DIARYLALKYL-SUBSTITUTED ALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THE SAME
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
DK386089A (en) * 1988-08-12 1990-02-13 Japan Tobacco Inc KATEKOLDERIVATER
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
JP2618195B2 (en) * 1991-09-24 1997-06-11 大日本製薬株式会社 Blood lipid metabolism improver
ZA931601B (en) * 1992-03-06 1993-10-05 Squibb & Sons Inc Microsomal triglyceride transfer protein
US5321031A (en) * 1992-09-23 1994-06-14 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of ACAT

Also Published As

Publication number Publication date
JPH07165712A (en) 1995-06-27
FI944048A (en) 1995-03-04
NO943260L (en) 1995-03-06
KR950008505A (en) 1995-04-17
AU7164294A (en) 1995-03-16
RU94031747A (en) 1996-07-20
HU9402542D0 (en) 1994-10-28
US6492365B1 (en) 2002-12-10
US20030166590A1 (en) 2003-09-04
PL304883A1 (en) 1995-03-06
US5789197A (en) 1998-08-04
HUT70613A (en) 1995-10-30
CA2131430A1 (en) 1995-03-04
US5595872A (en) 1997-01-21
NZ264372A (en) 1996-12-20
FI944048A0 (en) 1994-09-02
IL110803A0 (en) 1994-11-11
CN1106003A (en) 1995-08-02
ZA946772B (en) 1995-04-03
AU690125B2 (en) 1998-04-23
CZ212494A3 (en) 1995-08-16
EP0643057A1 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
NO943260D0 (en) Microsomal triglyceride transfer protein
FI932521A0 (en) Now endoglucan enzyme
DE69403556D1 (en) Micromanipulator
DE9401894U1 (en) heater
DE9314954U1 (en) Serving
IT1275679B1 (en) MULTIPLE THERMOSTAT
DE4498382D2 (en) Curling
DE9304980U1 (en) Contacting
DE9316192U1 (en) Multiple angles
AT400192B (en) HEATER
DE9404741U1 (en) heater
KR950008806U (en) Pared
KR950005872U (en) Eat
BR9304752A (en) Multiple contact
DE69409358D1 (en) ELECTROVISCAL FLUIDUM
NO934555L (en) Beger
DE9313478U1 (en) Whisk
KR950016614U (en) Chopsticks
SE9304197D0 (en) hot top
FI621U1 (en) Plan
SE9303466D0 (en) Heat
ITMI931038A0 (en) MULTIPLE DENSOSTAT
KR950005537U (en) Chopstick Support
DE59501062D1 (en) Transfer case
KR950007769U (en) Squid Heater